Are the EEG microstates correlated with motor and non-motor parameters in patients with Parkinson's disease?

Neurophysiol Clin. 2023 Feb;53(1):102839. doi: 10.1016/j.neucli.2022.102839. Epub 2023 Jan 28.

Abstract

Objectives: This study compared electroencephalography microstates (EEG-MS) of patients with Parkinson's disease (PD) to healthy controls and correlated EEG-MS with motor and non-motor aspects of PD.

Methods: This cross-sectional exploratory study was conducted with patients with PD (n = 10) and healthy controls (n = 10) matched by sex and age. We recorded EEG-MS using 32 channels during eyes-closed and eyes-open conditions and analyzed the four classic EEG-MS maps (A, B, C, D). Clinical information (e.g., disease duration, medications, levodopa equivalent daily dose), motor (Movement Disorder Society - Unified Parkinson Disease Rating Scale II and III, Timed Up and Go simple and dual-task, and Mini-Balance Evaluation Systems Test) and non-motor aspects (Mini-Mental State Exam [MMSE], verbal fluency, Hospital Anxiety and Depression Scale, and Parkinson's Disease Questionnaire-39 [PDQ-39]) were assessed in the PD group. Mann-Whitney U test was used to compare groups, and Spearman's correlation coefficient to analyze the correlations between coverage of EEG-MS and clinical aspects of PD.

Results: The PD group showed a shorter duration of EEG-MS C in the eyes-closed condition than the control group. We observed correlations (rho = 0.64 to 0.82) between EEG-MS B, C, and D and non-motor aspects of PD (MMSE, verbal fluency, PDQ-39, and levodopa equivalent daily dose).

Conclusion: Alterations in EEG-MS and correlations between topographies and cognitive aspects, quality of life, and medication dose indicate that EEG could be used as a PD biomarker. Future studies should investigate these associations using a longitudinal design.

Keywords: Biomarkers; Brain waves; Diagnostic techniques; Neurodegenerative disease; Parkinsonian disorders.

MeSH terms

  • Cross-Sectional Studies
  • Electroencephalography
  • Humans
  • Levodopa / therapeutic use
  • Parkinson Disease* / diagnosis
  • Parkinson Disease* / drug therapy
  • Quality of Life

Substances

  • Levodopa